NATIONAL INSTITUTES OF HEALTH
πΊπΈUnited States
- Country
- πΊπΈUnited States
- Ownership
- Subsidiary, Private
- Established
- 1948-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.nidcr.nih.gov
Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma
Phase 2
Completed
- Conditions
- Ciliary Body and Choroid Melanoma, Medium/Large SizeExtraocular Extension MelanomaIris MelanomaUveal MelanomaRecurrent Intraocular MelanomaRecurrent MelanomaStage IV Melanoma
- Interventions
- First Posted Date
- 2005-07-21
- Last Posted Date
- 2019-01-29
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 32
- Registration Number
- NCT00121225
- Locations
- πΊπΈ
Fox Chase Cancer Center, Rockledge, Pennsylvania, United States
π¨π¦Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada
π¨π¦Princess Margaret Hospital Phase 2 Consortium, Toronto, Ontario, Canada
17-AAG and Sorafenib in Treating Patients With Unresectable or Metastatic Solid Tumors
Phase 1
Completed
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- Other: laboratory biomarker analysisOther: pharmacological studyProcedure: magnetic resonance imaging
- First Posted Date
- 2005-07-21
- Last Posted Date
- 2014-06-17
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 54
- Registration Number
- NCT00121264
- Locations
- πΊπΈ
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
Combination Chemo, Rituximab, and Bevacizumab in Older Patients With Stage II-IV Diffuse Large B-Cell Lymphoma
Phase 2
Completed
- Conditions
- Contiguous Stage II Adult Diffuse Large Cell LymphomaNoncontiguous Stage II Adult Diffuse Large Cell LymphomaStage III Adult Diffuse Large Cell LymphomaStage IV Adult Diffuse Large Cell Lymphoma
- Interventions
- Biological: rituximabBiological: bevacizumabOther: laboratory biomarker analysis
- First Posted Date
- 2005-07-21
- Last Posted Date
- 2014-05-21
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 73
- Registration Number
- NCT00121199
- Locations
- πΊπΈ
SWOG, Portland, Oregon, United States
SJG-136 in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery
Phase 1
Completed
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- First Posted Date
- 2005-07-21
- Last Posted Date
- 2014-02-24
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 39
- Registration Number
- NCT00121290
- Locations
- πΊπΈ
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
Sorafenib, Gemcitabine, and Capecitabine in Treating Patients With Unresectable and/or Metastatic Kidney Cancer
Phase 1
Completed
- Conditions
- Recurrent Renal Cell CarcinomaStage IV Renal Cell Cancer AJCC v7Stage III Renal Cell Cancer AJCC v7
- Interventions
- First Posted Date
- 2005-07-21
- Last Posted Date
- 2021-04-06
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 17
- Registration Number
- NCT00121251
- Locations
- πΊπΈ
Weill Medical College of Cornell University, New York, New York, United States
πΊπΈMontefiore Medical Center - Moses Campus, Bronx, New York, United States
πΊπΈLaura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York, United States
Cilengitide in Treating Patients With Prostate Cancer
Phase 2
Completed
- Conditions
- Recurrent Prostate CancerStage IIA Prostate CancerStage III Prostate CancerStage IIB Prostate CancerStage I Prostate Cancer
- Interventions
- First Posted Date
- 2005-07-21
- Last Posted Date
- 2016-04-28
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 16
- Registration Number
- NCT00121238
- Locations
- πΊπΈ
University of Michigan University Hospital, Ann Arbor, Michigan, United States
Long-Term Lamivudine Therapy for Chronic Hepatitis B
Phase 4
Completed
- Conditions
- Hepatitis B, Chronic
- First Posted Date
- 2005-07-15
- Last Posted Date
- 2017-07-02
- Target Recruit Count
- 50
- Registration Number
- NCT00120354
- Locations
- πΊπΈ
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Bevacizumab and Combination Chemotherapy in Patients With Lymph Node Positive Breast Cancer
Phase 2
Completed
- Conditions
- Male Breast CancerStage II Breast CancerStage IIIA Breast CancerStage IIIB Breast Cancer
- Interventions
- Biological: bevacizumabBiological: filgrastimBiological: pegfilgrastimRadiation: radiation therapyDrug: aromatase inhibition therapy
- First Posted Date
- 2005-07-13
- Last Posted Date
- 2014-05-15
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 226
- Registration Number
- NCT00119262
- Locations
- πΊπΈ
Eastern Cooperative Oncology Group, Boston, Massachusetts, United States
17-AAG and Irinotecan in Treating Patients With Locally Advanced or Metastatic Solid Tumors
Phase 1
Completed
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- First Posted Date
- 2005-07-13
- Last Posted Date
- 2013-06-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 48
- Registration Number
- NCT00119236
- Locations
- πΊπΈ
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Sorafenib in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery
Phase 2
Completed
- Conditions
- Stage III MelanomaStage IV Melanoma
- Interventions
- Other: laboratory biomarker analysis
- First Posted Date
- 2005-07-13
- Last Posted Date
- 2013-01-15
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 74
- Registration Number
- NCT00119249
- Locations
- πΊπΈ
Montefiore Medical Center, Bronx, New York, United States